Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population

Amerlöv, Conny; Emdin, Stefan O.; Lundgren, Bengt; Roos, Göran; Söderström, Jan; Bjersing, Lars; Norberg, Curt; Ängquist, Karl‐Axel

doi:10.1002/1097-0142(19921001)70:7<1928::aid-cncr2820700720>3.0.co;2-r

Cited by 34 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; Amerlöv et al . ) and between 61 and 269 days for adenocarcinoma of the lung (Schwartz ; Spratt et al . ; Weiss ).…”

Section: Methodsmentioning

confidence: 99%

“…Growth rates of tumors can be estimated from the reports of the tumor volume doubling time. Average reported volume doubling times of breast cancer range between 105 and 270 days (Kusama et al 1972;Amerlöv et al 1992) and between 61 and 269 days for adenocarcinoma of the lung (Schwartz 1961;Spratt et al 1963;Weiss 1974). It follows that the average growth coefficient of these advanced tumors can vary from 0.008 to 0.035, assuming 3 days between cell divisions.…”

Section: Parameter Selectionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of one additional driver mutation on tumor progression

Reiter

Božić

Allen

et al. 2012

Evolutionary Applications

View full text Add to dashboard Cite

Tumor growth is caused by the acquisition of driver mutations, which enhance the net reproductive rate of cells. Driver mutations may increase cell division, reduce cell death, or allow cells to overcome density-limiting effects. We study the dynamics of tumor growth as one additional driver mutation is acquired. Our models are based on two-type branching processes that terminate in either tumor disappearance or tumor detection. In our first model, both cell types grow exponentially, with a faster rate for cells carrying the additional driver. We find that the additional driver mutation does not affect the survival probability of the lesion, but can substantially reduce the time to reach the detectable size if the lesion is slow growing. In our second model, cells lacking the additional driver cannot exceed a fixed carrying capacity, due to density limitations. In this case, the time to detection depends strongly on this carrying capacity. Our model provides a quantitative framework for studying tumor dynamics during different stages of progression. We observe that early, small lesions need additional drivers, while late stage metastases are only marginally affected by them. These results help to explain why additional driver mutations are typically not detected in fast-growing metastases.

show abstract

“…; Amerlöv et al . ) and between 61 and 269 days for adenocarcinoma of the lung (Schwartz ; Spratt et al . ; Weiss ).…”

Section: Methodsmentioning

confidence: 99%

Section: Parameter Selectionmentioning

confidence: 99%

The effect of one additional driver mutation on tumor progression

Reiter

Božić

Allen

et al. 2012

Evolutionary Applications

View full text Add to dashboard Cite

show abstract

“…Mammography studies (49, 50) have shown that primary breast tumors have an average doubling time of 157 days (32) varying between 44 and >1,800 days during exponential growth (51). Thus, the growth of a tumor from initiation to a size of 1-cm (52), which is the limitation of most current imaging tools, requires an average of 12 years.…”

Section: The Pathogenesis Of Metastasismentioning

confidence: 99%

AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective

2010

View full text Add to dashboard Cite

Metastases resistant to therapy is the major cause of death from cancer. Despite almost 200 years of study, the process of tumor metastasis remains controversial. Stephen Paget initially identified the role of host-tumor interactions on the basis of a review of autopsy records. His “seed and soil” hypothesis was substantiated a century later with experimental studies and numerous reports have confirmed these seminal observations. Inarguably, an improved understanding of the metastatic process and the attributes of the cells selected by this process are critical to the treatment of patients with systemic disease. In many patients, metastasis has occurred by the time of diagnosis, such that metastasis prevention may not be relevant, and treatment of systemic disease, as well as the identity of patients with early disease, should be our goal. During the last three decades, revitalized research has focused on new discoveries in the biology of metastasis. While our understanding of the molecular events that regulate metastasis has improved; nonetheless, the relevant contributions and timing of molecular lesion(s) potentially involved in its pathogenesis remain unclear. The history of pioneering observations and discussion of current controversies should help investigators understand the complex and multifactorial interactions between the host and selected tumor cells that contribute to fatal metastasis and allow for the design of successful therapy.

show abstract

“…Arnerlöv and colleagues 122 analysed the doubling time of tumours based on information from 158 patients with breast cancer who were diagnosed between 1974 and 1987 in Sweden. The authors found large variations in tumour doubling rates.…”

Section: Appendix 1 Appendixmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation

2012

Clinical Governance: An International Journal

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indir...

show abstract

Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population

Cited by 34 publications

References 29 publications

The effect of one additional driver mutation on tumor progression

The effect of one additional driver mutation on tumor progression

AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective

The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation

Contact Info

Product

Resources

About